The Food and Drug Administration (FDA) has approved Ivax Pharmaceutical’s Esomeprazole Magnesium Delayed-Release Capsules, the first generic version of AstraZeneca’s Nexium.

Nexium is currently approved as triple therapy (w. amoxicillin + clarithromycin) for H. pylori eradication in duodenal ulcer disease, short-term treatment and maintenance of healing of erosive esophagitis (EE), symptomatic GERD, short-term treatment of EE due to acid-mediated GERD in infants 1 month–<1 year, to reduce risk of NSAID-associated gastric ulcer, and as long-term treatment of pathological hypersecretory conditions (eg, Zollinger-Ellison syndrome).

RELATED: GERD Management Algorithm

Esomeprazole is a proton pump inhibitor that suppresses gastric acid secretion by specific inhibition of the H+/K+-ATPase in the gastric parietal cell. By specifically acting on the proton pump, esomeprazole blocks the final step in acid production, thus reducing gastric acidity.

Esomeprazole Magnesium Delayed-Release Capsules will be available in 20mg and 40mg strengths.

For more information visit